title: Interaction of the papillomavirus E8--E2C protein with the cellular CHD6 protein contributes to transcriptional repression.
abstract: Expression of the E6 and E7 oncogenes of high-risk human papillomaviruses (HPV) is controlled by cellular transcription factors and by viral E2 and E8--E2C proteins, which are both derived from the HPV E2 gene. Both proteins bind to and repress the HPV E6/E7 promoter. Promoter inhibition has been suggested to be due to binding site competition with cellular transcription factors and to interactions of different cellular transcription modulators with the different amino termini of E2 and E8--E2C. We have now identified the cellular chromodomain helicase DNA binding domain 6 protein (CHD6) as a novel interactor with HPV31 E8--E2C by using yeast two-hybrid screening. Pull-down and coimmunoprecipitation assays indicate that CHD6 interacts with the HPV31 E8--E2C protein via the E2C domain. This interaction is conserved, as it occurs also with the E8--E2C proteins expressed by HPV16 and -18 and with the HPV31 E2 protein. Both RNA knockdown experiments and mutational analyses of the E2C domain suggest that binding of CHD6 to E8--E2C contributes to the transcriptional repression of the HPV E6/E7 oncogene promoter. We provide evidence that CHD6 is also involved in transcriptional repression but not activation by E2. Taken together our results indicate that the E2C domain not only mediates specific DNA binding but also has an additional role in transcriptional repression by recruitment of the CHD6 protein. This suggests that repression of the E6/E7 promoter by E2 and E8--E2C involves multiple interactions with host cell proteins through different protein domains.
authors.affiliation: University Hospital Tuebingen, Institute for Medical Virology and Epidemiology of Viral Diseases, Division of Experimental Virology, Elfriede-Aulhorn-Str. 6, D-72076 Tuebingen, Germany.
authors.forename: Jasmin
authors.initials: J
authors.lastname: Fertey
authors.forename: Ingo
authors.initials: I
authors.lastname: Ammermann
authors.forename: Michael
authors.initials: M
authors.lastname: Winkler
authors.forename: Reinhard
authors.initials: R
authors.lastname: Stöger
authors.forename: Thomas
authors.initials: T
authors.lastname: Iftner
authors.forename: Frank
authors.initials: F
authors.lastname: Stubenrauch
mesh_terms: D004265:DNA Helicases / Q000378:metabolism*; D004268:DNA-Binding Proteins / Q000378:metabolism*; D015536:Down-Regulation; D054884:Host-Pathogen Interactions; D052162:Human papillomavirus 16 / Q000472:pathogenicity*; D006801:Humans; D047468:Immunoprecipitation; D009419:Nerve Tissue Proteins / Q000378:metabolism*; D009856:Oncogene Proteins, Viral / Q000096:biosynthesis* / Q000378:metabolism; D011485:Protein Binding; D025941:Protein Interaction Mapping; D014158:Transcription, Genetic; D020798:Two-Hybrid System Techniques; D014764:Viral Proteins / Q000378:metabolism*
chemical_list: D004268:DNA-Binding Proteins; C054855:E2 protein, Human papillomavirus type 16; C098597:E2 protein, Human papillomavirus type 31; D009419:Nerve Tissue Proteins; D009856:Oncogene Proteins, Viral; D014764:Viral Proteins; C069102:oncogene protein E2, Human papillomavirus type 18; D004265:DNA Helicases; C471926:CHD5 protein, human